Cytokinetics Ownership | Who Owns Cytokinetics?
Cytokinetics Ownership Summary
Cytokinetics is owned by 43.15% institutional investors, 0.70% insiders, and 56.15% retail investors. Blackrock funding, inc. /de is the largest institutional shareholder, holding 16.30% of CYTK shares. T. Rowe Price Capital Appreciation is the top mutual fund, with 4.63% of its assets in Cytokinetics shares.
CYTK Ownership Benchmark
| Type | Name | % Inst | % Insiders | % Retail |
|---|---|---|---|---|
| Stock | Cytokinetics | 43.15% | 0.70% | 56.15% |
| Sector | Healthcare Stocks | 35.56% | 12.08% | 52.36% |
| Industry | Biotech Stocks | 35.43% | 12.01% | 52.56% |
Institutional Shareholders
Top Institutional Shareholders by Total Shares
| Holder | Shares | % Holding | Value |
|---|---|---|---|
| Blackrock funding, inc. /de | 20.09M | 16.30% | $1.71B |
| Blackrock | 14.67M | 14.40% | $794.97M |
| T. rowe price investment management | 17.52M | 14.36% | $1.15B |
| Vanguard group | 12.05M | 10.04% | $765.54M |
| Fmr | 10.72M | 8.79% | $706.76M |
| Wellington management group llp | 8.01M | 6.56% | $527.91M |
| State street | 6.49M | 5.27% | $553.24M |
| Tudor investment corp et al | 6.00M | 5.02% | $6.86M |
| Avoro capital advisors | 3.33M | 2.73% | $219.70M |
| Geode capital management | 3.22M | 2.64% | $211.97M |
Top Institutional Shareholders by % of Total Assets
| Holder | Shares | % Assets | Value |
|---|---|---|---|
| Rp management | 980.39K | 22.73% | $51.76M |
| Foresite capital management iv | 503.30K | 13.99% | $33.17M |
| Sarissa capital management lp | 228.62K | 9.56% | $15.07M |
| Boxer capital | 2.10M | 5.99% | $113.78M |
| Melqart asset management (uk) | 843.95K | 5.48% | $55.62M |
| Integral health asset management | 1.60M | 5.04% | $105.46M |
| Checkpoint capital | 180.00K | 4.26% | $11.86M |
| Gsk | 340.43K | 3.75% | $22.44M |
| Monashee investment management | 100.00K | 3.59% | $6.59M |
| Exome asset management | 103.72K | 3.54% | $6.84M |
Top Buyers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Tudor investment corp et al | 6.00M | 0.01% | 6.00M |
| Blackrock funding, inc. /de | 20.09M | 0.03% | 3.55M |
| Avoro capital advisors | 3.33M | 2.16% | 3.33M |
| Blackrock | 14.67M | 0.02% | 2.26M |
| Paradigm biocapital advisors lp | 1.48M | 1.99% | 1.48M |
Top Sellers
| Holder | Shares | % Assets | Change |
|---|---|---|---|
| Darwin global management | - | - | -4.58M |
| Fmr | 10.72M | 0.04% | -2.08M |
| Deep track capital, lp | 1.37M | 1.48% | -1.96M |
| Pfm health sciences, lp | - | - | -1.76M |
| Westfield capital management co lp | - | - | -1.31M |
New Positions
| Holder | Shares | % Assets | Change | Value |
|---|---|---|---|---|
| Tudor investment corp et al | 6.00M | 0.01% | 6.00M | $6.86M |
| Avoro capital advisors | 3.33M | 2.16% | 3.33M | $219.70M |
| Paradigm biocapital advisors lp | 1.48M | 1.99% | 1.48M | $97.60M |
| Norges bank | 1.02M | 0.01% | 1.02M | $86.51M |
| Balyasny asset management | 992.54K | 0.08% | 992.54K | $65.42M |
Sold Out
| Holder | Change |
|---|---|
| New england capital financial advisors | -1.00 |
| Td private client wealth | -2.00 |
| Financial gravity asset management | -2.00 |
| Strategic advocates | -2.00 |
| Ross\johnson & associates | -2.00 |
Institutional Ownership Trends
| Date | Holdings | Change % | Shares | Change % | Ownership | Change % | Increased Position | Change % | Decreased Position | Change % |
|---|---|---|---|---|---|---|---|---|---|---|
| Mar 31, 2026 | 258 | -45.45% | 51,788,965 | -62.86% | 43 | 0.32% | 147 | -42.35% | 69 | -46.92% |
| Dec 31, 2025 | 328 | -22.64% | 72,535,010 | -48.66% | 60 | 0.43% | 182 | -19.82% | 87 | -18.69% |
| Sep 30, 2025 | 403 | 16.47% | 144,458,231 | 4.66% | 120 | 0.91% | 217 | 25.43% | 105 | -0.94% |
| Jun 30, 2025 | 344 | -10.88% | 137,969,518 | 1.88% | 115 | 0.88% | 171 | -14.50% | 106 | -0.93% |
| Mar 31, 2025 | 25 | -93.40% | 16,158,180 | -87.73% | 13 | 0.11% | 15 | -91.28% | 5 | -96.09% |
Top Mutual Funds Shareholders
| Holder | Shares | % Holding | Change |
|---|---|---|---|
| T. Rowe Price Capital Appreciation | 6.29M | 4.63% | 1.18M |
| iShares Core S&P Mid-Cap ETF | 4.66M | 3.36% | 143.00 |
| Vanguard Morn Total Stk Mkt Idx Investor | 4.32M | 3.18% | 30.41K |
| Vanguard Total Stock Mkt Idx Inv | 4.32M | 3.18% | 30.41K |
| Vanguard US Total Market Shares ETF | 3.75M | 3.15% | 128.42K |
| iShares Russell 2000 ETF | 3.34M | 2.41% | -59.42K |
| Vanguard Small Cap Index | 3.11M | 2.29% | 23.91K |
| Vanguard Health Care Inv | 3.11M | 2.24% | -958.85K |
| American Funds SMALLCAP World A | 3.00M | 2.21% | 882.15K |
| SPDR® S&P Biotech ETF | 2.07M | 1.73% | 4.61K |
Recent Insider Transactions
| Date | Name | Role | Activity | Value |
|---|---|---|---|---|
| Aug 10, 2026 | Blum Robert I | President & CEO | Sell | $575.70K |
| Jul 30, 2026 | Callos Andrew | EVP, Chief Commercial Officer | Sell | $1.12M |
| Jul 27, 2026 | Blum Robert I | President & CEO | Sell | $606.52K |
| Jul 21, 2026 | Malik Fady Ibraham | EVP Research & Development | Sell | $282.06K |
| Jul 13, 2026 | Blum Robert I | President & CEO | Sell | $614.33K |
Insider Transactions Trends
| Date | Buy | Sell |
|---|---|---|
| 2026 Q3 | - | 9 |
| 2026 Q2 | - | 25 |
| 2026 Q1 | - | 22 |
| 2025 Q4 | - | 20 |
| 2025 Q3 | - | 15 |
CYTK Ownership FAQ
Try Tickergate Pro Free
Customize Everything. 100% Flexibility. Fast and Easy to Use (No code or Excel Needed)
Customize your own personal stocks lists, views and charts
Choose from hundreds of fields, up to 15 years of history
Conduct deep comparison analysis
Discover trending investment themes
Find your next best investment
Research stocks using tools